FluoGuide is trading 6.4% down now at SEK 35.10 after reversing its recent rally.
- The latest official release remains the August 25, 2026 Q2 interim report.
- FDA approval for the first U.S. high-grade glioma trial site and Fast Track designation were positive developments.
- No negative September 2, 2026 announcement was identified; with biotech momentum positive, the move appears to reflect unexplained profit-taking or volatility.